Herpes, HPV & Hepatitis C Defeated by Gene-Eden-VIR in Post-Marketing Clinical Study
People with a herpes virus (HSV-1), (HSV-2), Human Papillomavirus (HPV), Cytomegalovirus (CMV), Epstein Barr Virus (EBV), and even the Hepatitis C virus (HCV), can breathe a little easier.
The journal Pharmacology & Pharmacy, in a special edition on advances in antiviral drugs, published a study that showed that a natural product called Gene-Eden-VIR safely and effectively reduces viral symptoms associated with the viruses mentioned above. The study was published on August 12, 2013.
According to the study, Gene-Eden-VIR reduced symptoms such as genital
warts, low and high grade cervical dysplasia, abnormal Pap smear results) and general symptoms (blisters, cold sores, hives, skin tabs, panic attacks, depression, kidney
problems, sleeping problems, liver problems, fever, fatigue, sore throat, swollen lymph nodes, diarrhea, and even weight loss.
The study is very interesting since it is a first of its kind. Basically, it is a clinical study that used the same controls as required by the FDA for pharmaceutical drug testing. In contrast, most companies that sell natural products don’t do any kind of clinical testing.
The developer of Gene-Eden-VIR, by the way, is a company called polyDNA. They develop and market natural, antiviral products based on a scientific theory put forth by Dr. Hanan Polansky. That theory is called “Microcompetition with Foreign DNA.” The theory explains how foreign DNA fragments, and specifically, DNA of latent viruses, can cause most major diseases.
It is also interesting how Gene-Eden-VIR was developed. The study said that this natural product was formulated by analyzing thousands of scientific papers with a psycho-linguistic computer program called simply enough: “Computer Intuition.” The idea behind the program is fairly simple. Every future event is preceded by hints, and the key to predicting these future events is recognizing their significance.
Since this computer program successfully predicted the results of the clinical study, it can (and probably should) be used by other biotech and pharmaceutical companies in their R&D efforts. After all, having an accurate predictor of clinical results would be an amazing benefit to these companies. It could potentially save hundreds of thousands of dollars, and could be a great boon to companies suffering from an R&D productivity crisis.
At the end of the day, however, the real importance of this study is that it gives doctors and other healthcare practitioners confidence in recommending Gene-Eden-VIR to patients suffering from HSV, HPV, EBV, CMV, and HCV. It’s well-known that most of the FDA approved drugs against these viruses have side effects. As the study authors wrote, “…healthcare practitioners should recommend Gene-Eden-VIR as a safe and effective antiviral treatment to individuals infected with these viruses.”